Editorial methodology
How we choose featured affiliate partners
The providers we feature on the homepage are a disclosed affiliate shortlist, not a care-quality ranking. A provider leaves the list when current evidence makes the placement hard to defend, so it can hold fewer than five. Below you see who is featured now, then the rules each one has to pass.
Who is featured right now

Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
7.6/10 · GoodChecked Oct 16, 2026; a rating claim didn't match Trustpilot.Read our Embody review
Plus $199/year membership after 21 days · checked Oct 17
7.2/10 · FairChecked Sep 15, 2026; some details not published.Read our Collective reviewCompounded semaglutide · yearly plan · checked Nov 15
7.6/10 · GoodChecked Oct 16, 2026; a rating claim didn't match Trustpilot.Read our Gala review
These are affiliate partners. We earn a commission when you join through these links.
Two lists, two different jobs
We offer two ways to explore GLP-1 telehealth providers, and we keep them clearly separate so readers can tell which is which:
- The program finder on our homepage helps readers explore medication, format and qualified prices. It is not a completed care-quality ranking. Our assessment framework has five weighted factors:
- Pricing (25%)
- Clinical oversight (25%)
- Medication options (20%)
- User experience (15%)
- Transparency (15%)
Published numbers may come from incomplete or unreconciled assessments. They do not establish that one program is better or worse than another. Read the limitations with each score and our editorial policy for the assessment framework.
Affiliate status never changes a score. A payment also cannot turn missing evidence into a verified strength or establish the quality of a provider's care.
- Featured affiliate partners (the commercial cards on the homepage) are editorial and commercial, not a comparative score ranking. Only providers that remain eligible under the current evidence can appear, so the number of placements is allowed to shrink.
A reader gets both: the curated shortlist for “just tell me what to look at first” intent, and the program finder for “show me the data so I can decide for myself” intent.
Featured placement is separate from name and price ordering. A commercial placement does not change a provider's recorded price, assessment or evidence limitations.
How we curate featured placements
Every placement must clear all of these criteria. If new evidence makes a provider unsafe or misleading to promote, it leaves the list regardless of payout or conversion history.
- No disqualifying current evidence. An unresolved regulatory action, a corroborated systemic fulfillment pattern, or another material reader-risk finding can remove a provider immediately. Score and revenue cannot override that evidence.
- Active, approved affiliate relationship. We're honest that this is a list optimized for active monetization. We label it as such and disclose it on every page.
- Price and product claims we can describe honestly. Introductory rates, plan commitments, medication-only figures, and unresolved totals must be labeled as such. A low headline never becomes an all-in promise merely because the provider is a partner.
- A defensible niche or differentiator. If a provider doesn't serve a distinguishable use case (cash-pay flat-rate, insurance-friendly, oral GLP-1, etc.), they're a duplicate of a stronger pick and don't earn the slot.
- Re-evaluated when evidence changes. Price drift, complaint patterns, regulatory actions, fulfillment failures, or product changes can remove a placement before any scheduled review. We do not add a weaker replacement just to restore a card count.
What earns a slot vs. what doesn't
What can affect commercial order: measured conversion performance and payout, but only among providers that already clear the evidence rules above.
That is the legitimate place for affiliate economics to play a role: ordering a plainly labeled commercial shortlist after editorial eligibility has been established.
What doesn't: a higher affiliate payout cannot rescue a provider with disqualifying evidence, and it never moves a provider up the methodology score. Two different lists, two different rules.
Disclosures
We earn commissions on sign-ups to the providers above. Revenue can order eligible commercial placements, but it cannot change a score, an objective rank, or the evidence threshold for appearing here. Read the full affiliate disclosure and editorial policy for the integrity firewall in detail.
Where to go next
Ready to pick a provider? Take our 2-minute match quiz, compare the cheapest GLP-1 options, or browse the full best GLP-1 providers for 2026.


